MedPath

Development and Validation of a Digital Optotype for Near Vision in Greek Language.

Completed
Conditions
Presbyopia
Low Vision
Near Vision
Interventions
Diagnostic Test: MNREAD testing
Registration Number
NCT04242836
Lead Sponsor
Democritus University of Thrace
Brief Summary

Primary objective of our study is to develop and validate a computer-based digital near-vision optotype based on the Greek version of the print MNREAD.

Detailed Description

Present study aims to develop and validate a computer-based digital near-vision optotype based on the Greek version of the print MNREAD.

Specifically, it aims to evaluate the level of agreement between the conventional printed greek MNREAD chart and the corresponding digital chart, as well as test-retest reliability of the digital optotype.

To address these aims, four reading parameters measured with the print and the digital version are compared. These parameters are the following:

1. Reading Acuity (RA)

2. Maximum Reading Speed (MRS)

3. Critical Print Size (CPS)

4. Accessibility Index (ACC)

All the comparisons take place in two groups: a) a Normal Vision Group (NVG), and b) a Low Vision Group (LVG) in order to estimate the reading capacity in a population with a wide range of vision.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria
  • adequate literacy of written Greek language
Exclusion Criteria
  • dyslexia
  • attention-deficiency
  • former diagnosis of mental diseases
  • former diagnosis of psychiatric diseases

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Control groupMNREAD testing1. 70 patients with normal vision (NVG) with adequate literacy of written Greek language 2. 30 patients with low vision (LVG) with adequate literacy of written Greek language These patients are tested on the printed Greek MNREAD
Study groupMNREAD testingThe same patients as those in the control group (NVG, LVG) are tested on the digital version of the Greek MNREAD (DeDART)
Primary Outcome Measures
NameTimeMethod
Accessibility Index (ACC)through study completion, an average of 8 months

The mean reading speed measured across the 10 largest print sizes (1.3 to 0.4 logMAR) of the MNREAD Acuity Chart at 40 cm normalized by 200 wpm, which was the mean value for a group of 365 normally sighted young adults aged 18 to 39 years old.

Reading Acuity (RA)through study completion, an average of 8 months

The smallest print that the patient can read without making significant errors, and can be calculated by the following formula:

Acuity (in logMAR)= 1.4 - (sentences x 0.1) + (errors x 0.01).

Critical Print Size (CPS)through study completion, an average of 8 months

The smallest print size at which patients can read with their MRS, and is identified as the print size of the sentence fulfilling this criterion: all of the following sentences are read at a speed that is 1.96 times the standard deviation below the average of the larger preceding sentences (that is the MRS). In other words, it is defined as the smallest print size that yields 90% of the MRS \[(in logMAR)\]

Maximum Reading Speed (MRS)through study completion, an average of 8 months

The patient's reading speed when reading is not limited by print size , and is calculated by averaging the speed of the sentences with print size larger than the CPS. \[(in words per minute (wpm)\]

Secondary Outcome Measures
NameTimeMethod
Intraclass Correlation Coefficients (ICCs) for study participantsthrough study completion, an average of 8 months

Level of agreement between the print and the digital version are evaluated by calculation of the ICCs for the 4 reading parameters (RA, MRS, CPS, ACC).

Test-retest Intraclass Correlation Coefficients (ICCs)through study completion, an average of 8 months

Test-retest reliability of the digital optotype is evaluated by ICCs for the 4 reading parameters (RA, MRS, CPS, ACC)..

Trial Locations

Locations (1)

University Hospital of Alexandroupolis

🇬🇷

Alexandroupolis, Evros, Greece

© Copyright 2025. All Rights Reserved by MedPath